Examples of research studies on the effects of ZnO-NPs on fish.
Zinc oxide nanoparticles (ZnO-NPs) are among nanoscale materials displaying exponentially growing production due to their applications in the field of cosmetology, medicine, as antibacterial agent and catalyst. The ZnO nanomaterials release into the aquatic ecosystems through domestic and industrial wastewaters has the potential to induce pernicious effects on fish and other organisms. Increasing concerns on the environmental hazard to aquatic biota have been highlighted by the toxic potential of some metal-based nanomaterials. Several characteristics of ZnO-NPs (e.g. size, shape, surface charge and agglomeration state) play a central role in biological effects such as genotoxic, mutagenic or cytotoxic effects. Overall, Zn bioaccumulation, histopathological, and hematological changes with oxidative and cellular stress have been reported in ZnO-NPs exposed animals.
- zinc oxide nanoparticles (ZnO-NPs)
- human health
1.1. Applications of zinc oxide nanoparticles
Zinc oxide nanoparticles (ZnO-NPs) are commonly used in several domains of human activity such as cosmetics, paints, optoelectronics, and pharmaceuticals, due to their low cost and interesting properties (e.g., conductivity, chemical stability, catalytic properties, photonics and optoelectronics, antibacterial, antifungal, and UV filtering properties). ZnO-NPs are highly used in the cosmetic industry, typically in sunscreens and facial creams . In the biomedical field, ZnO-NPs have been applied in cell imaging [2, 3], drug delivery, and have demonstrated promising results in cancer research (for review see [4, 5]).
ZnO-NPs have shown to decrease the viability of cultured cell lines derived from human cancers. ZnO-NPs induced a 50% reduction in cell viability in MCF7 (breast cancer) and A549 (lung cancer) cell cultures, at a very low concentration (31.2 μg ml−1), with size-dependent effectiveness . A high toxicity on T98G (brain cancer) cells, moderate toxicity on KB (skin cancer) cells, and low toxicity on normal human HEK cells have also been reported . ZnO-NPs have been proposed as genotoxic since they induced micronucleus in those cells. Apoptosis and intracellular production of reactive oxygen species (ROS) have been reported on melanoma cancer cells after exposure to different doses of ZnO-NPs . These nanomaterials also exhibited activity against HepG2 (liver cells) cells depending on the dose . A time-dependent reduction in the viability of murine cancer cells after exposure of ZnO-NPs was recently documented by . ZnO-NPs strong protein adsorption properties may also lead to its use in other biomedical applications. ZnO-NPs may be used to modulate metabolism and cellular responses, and have been proven useful for the detection of low levels of biomarkers (e.g., proteins/peptides ). ZnO-NPs have shown promising results as cholesterol sensors, controlling diabetes and hyperglycemia, modulation of some allergic reactions, via inhibition of mast cell degranulation  as well in tissue engineering scaffolds to enhance angiogenesis .
As for other nanoparticles, ZnO-NPs may also be toxic for some microorganisms, making them potential antibacterial, antifungal, and antiviral agents. This is an important feature of these nanomaterials considering the increasing concerns related to the proliferation of pathogenic microorganisms that are multiresistant to conventional antibiotics. ZnO-NPs may interact with the bacterial surface and/or with the bacterial core, exhibiting different bactericidal mechanisms. Antimicrobial properties of ZnO-NPs have been demonstrated on bacteria such as
ZnO-NPs synthesized by Nohynek et al. (2007), using wet chemical methods, revealed a high antibacterial activity, due to its inherent ability to absorb UV irradiation and optical transparency. This makes ZnO-NPs an important compound for the cosmetic industry, namely in formulations for sunscreens and facial creams . The antibacterial activities of ZnO-NPs, as mentioned above, significantly contribute to its value in food processing industry, as a potent sanitizing agent for disinfecting and sterilizing food industry equipment and containers against foodborne pathogenic bacteria. ZnO-NPs are able to disrupt
At industrial level, ZnO-NPs have various applications in catalysis and electronics . ZnO-NPs can be used in infrared and chemical sensors, in the manufacture of rubber and cigarettes (used as filter) and preparation of creams and ointments used to treat skin diseases. The range of possible applications of ZnO-NPs also includes agriculture. Studies have shown potential beneficial effects of ZnO-NPs on seed germination, water purification, and soil remediation. Peanut seeds treated with 25 nm ZnO-NPs (1000 ppm) displayed high germination, seeding vigor, and plant growth , while decreased ryegrass germination has been reported after ZnO-NPs exposure . Furthermore, the potential of ZnO-NPs to reduce microbial biomass and diversity  must also be taken into account.
1.2. Synthesis and characterization of ZnO nanoparticles
ZnO-based materials have been the subject of several reviews in the past years. A detailed survey on the literature concerning the synthesis and properties of nanosized ZnO can be found elsewhere . ZnO is an inorganic crystalline compound with a band-gap energy located in the UV region that widens as the size of the particles decreases below a threshold of a few nanometers. Both in the bulk form and as a nanoscale material, ZnO is an important material for several applications including in electronics and optical devices . ZnO-NPs may be synthesized by a variety of methods, selected based on the desired application, morphology, and size. Chemical and physical parameters (e.g., solvent type, precursors, pH, and temperature) are of high relevance in the synthesis protocols. A variety of shapes (nanorods, nanosphere, nanotubes, nanowires, nanoneedles, nanorings, spirals, drums, polyhedrons, disks, flowers, stars, boxes, and plates) may be produced, each displaying morphological-dependent physicochemical properties  that allow the exploitation of a variety of applications.
Some preparative methods include chemical vapor deposition, precipitation in aqueous solution, hydrothermal synthesis, sol-gel method, and synthesis using microemulsions and mechanochemical processes. These methods allow the production of particles differing in shape and size. Some available reviews present a thorough explanation of the principles and techniques involved in the different procedures . Briefly, the mechanochemical method is based on high-energy dry milling; the controlled precipitation method involves hydrolysis of a Zn(II) solution, in conditions that limit uncontrolled growth of particles, eventually followed by a thermal treatment to improve crystallinity; the hydrothermal method is a simple and environmentally friendly technique that involves the thermal treatment of Zn(II) aqueous solutions under auto-generated pressure, by using an autoclave as the reaction vessel. ZnO-NPs have also been prepared using a Zn(II) precursor in the presence of plant extracts [27, 28] as cost-effective approaches, with promising results in terms of bioapplications. Selected examples of synthesis methods for ZnO-NPs are presented below.
ZnO-NPs were synthesized by Aneesh et al.  by hydrothermal treatment of Zn(CH3COO2) 2H2O (0.1 M) solutions. ZnO-NPs were prepared by varying the growth temperature and concentration of the Zn(II) precursor. X-ray diffraction (XRD) performed on powdered samples revealed nanoparticles of
Soni and Koser  used a hydrolysis method for the synthesis of ZnO-NPs, with different concentrations of a surface-protecting agent (thioglycerol). UV-VIS spectroscopy revealed blueshifts in the absorption bands of the samples, as compared to the spectrum of typical bulk ZnO, as an indication for the presence of nanosized ZnO. The absorption band edge was observed in the UV region at wavelength 365, 362, and 364 nm for ZnO-NPs synthesized using 0.12, 0.3, and 0.5 ml of capping agent, respectively. The samples were composed of particles with average sizes between 3.5 and 3.9 nm, depending on the amount of molar concentration of the capping agent. Increasing the concentration of capping agent, the average particle size decreased and the respective band gap widens due to quantum size effects . Also using a hydrolysis method, Wang et al.  have synthesized nanometric ZnO using cetyltrimethylammonium bromide (CTAB) as surfactant. These authors reported high-crystalline nanoparticles of 50 nm average diameter. CTAB affected the process of nucleation and growth of crystallites during the synthesis also preventing the formation of ZnO agglomerates.
Giri et al.  synthesized hexagonal ZnO-NPs and nanorods by low-temperature oxidation of metallic Zn powder in the presence of acetic acid and trifluoroacetic acid. The final colorless powders were a first indication for the presence of ZnO. In this method, acetic acid and trifluoroacetic acid induced the growth of hexagonal-type ZnO-NPs and ZnO nanorods, respectively, whose crystalline nature was confirmed by XRD. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) images displayed hexagonal cross section of the nanoparticles and nanorods. The samples showed strong UV absorption peaked at 378 nm. A green synthesis method was used by Oudhia et al.  for ZnO nanotubes aiming biomedical application. For this purpose, neem leaf extract as biotemplate was used. The XRD pattern indicated the
Barreto et al.  synthesized ZnO-NPs by microwave-assisted method and checked the effect of precursor reagent, temperature, irradiation time, and additives on the morphology of synthesized nanoparticles by using (Zn(NO3)26H2O, Zn(CH3COO2)2H2O, or ZnCl2) as precursor. Radiation temperature of 80–140°C and increase in the irradiation time give high purity and homogenous size and shape of nanoparticles. The final pH is another important variable which causes significant changes in the morphology of the final particles. The addition of the anionic surfactant (AOT, sodium di-2-ethylhexyl sulfosuccinate) to the reaction medium allowed the synthesis of smaller particles. Kumar and Rani  synthesized ZnO-NPs by using microemulsions as nanoreactor for the synthesis of ZnO using ZnSO4 salt. The stable reverse micelle microemulsion was prepared by mixing a nonionic surfactant, Triton X-100, PVP (used as co-stabilizing agent), cyclohexane, and distilled water. XRD diffraction analysis shows the typical hexagonal
Tsuzuki and Cormick  synthesized nanocrystallites of ZnO of 26 nm size by a mechanochemical method using ZnCO3 as the precursor. It was observed that a milling time of 4 h was enough for the synthesis of ZnO-NPs. Song et al.  synthesized ellipsoidal ZnO-NPs with high crystal quality by another mechanochemical method. It was observed that depending on the solvent used, the ZnO-NPs remained dispersed with a mean diameter of 21 nm (nonpolar solvents), whereas in more polar solvents the nanoparticles gradually aggregated to a diameter of about 200 nm. Photoluminescence spectra of ZnO-NPs have been reported.
The routine methodologies used to characterize ZnO-NPs (colloids and powders) are those commonly applied to characterize other types of nanoparticles and include dynamic light scattering (DLS) techniques, UV-VIS absorption spectroscopy, selected area electron diffraction (SAED), and powder X-ray diffraction (XRD). The size and shape of the nanoparticles are directly analyzed by using microscopy (transmission electron microscopy—TEM, atomic force microscopy—AFM, or scanning electron—SEM). The crystalline phase (typically
2. Nanoparticles in aquatic systems
Increase in production and applications of ZnO-NPs is expected to result in its increased release into the environment. Ultimately, the aquatic ecosystems will probably be the main recipients, mainly as a result of industrial and domestic wastewaters . As one of the most produced nanoparticles in the European Union, with an estimated production of around 1600 t , ZnO-NPs environmental release may occur as early as their production, production of products containing nanoparticles, during their use and end of life of those products. Despite the knowledge that nanoparticles are increasingly being used in different fields of human activity, the quantification of their release in the environment, at any given time, is quite challenging due to the limited data on their current and expected prevalence in commercial products [40–42]. The technical difficulties associated with quantification of ZnO-NPs levels in the environment led to the need to predict environmental concentrations based on market penetration of nanomaterials, known usage of the products as well as fate/behavior. According to the available data, the theoretically predicted average environmental concentration of ZnO-NPs in European surface waters is 0.09 μg L−1 (with 85% confidence intervals: 0.05–0.29) . No standards have yet been established for permissible levels of nanoparticles in the environment. Nonetheless, in addition to dose, physicochemical properties of nanoparticles (e.g., size, shape, chemical composition, aggregation) as well as ionic strength and pH of receiving media play determinant roles on their behavior, bioavailability, and biological effects of nanoparticles . Once released into the environment, ZnO-NPs may display different behaviors. Nanoparticles in the environment may stay in suspensions as individual particles; dissolve; aggregate; form larger particles and ultimately sediment; adsorb onto water constituents (e.g., dissolved organic matter); transform chemically (e.g., due to redox reactions) or biologically (e.g., in the presence of microorganisms) in the marine environment . Once in the environment, most ZnO-NPs are likely to precipitate due to its poor colloidal stability . The available studies indicate that aggregation of ZnO-NPs, as for other nanoparticles, increases with ionic strength. In high ionic strength environments, reduction in electrostatic repulsion forces between the nanoparticles occurs, promoting aggregation and sedimentation. However, the presence of natural substances such as humic acids may help to steric and electrostatic stabilization of ZnO-NPs, aiding in their transport, mobility, and dispersion . Other highly relevant alterations that may occur in the environment and lead to toxic effects of ZnO-NPs are the dissolution and redox transformations. ZnO-NPs may dissolve, releasing Zn ions which may induce toxic effects , with reported faster dissolutions at smaller sizes . Redox reactions on ZnO-NPs’ surface may lead to the production of ROS, which are able to oxidize organic compounds and lead to oxidative stress. Thus, for risk assessments of nanoparticles such as ZnO-NPs, different factors have to be taken into account based on the wide variety of reactivities and properties of a particular type of nanoparticle .
The available studies on the behavior of ZnO-NPs in water systems have been performed under laboratory conditions, focusing mostly on freshwater. Available data indicate that dissolution is dependent on concentration, with the lowest dissolution percentage at the highest ZnO concentrations .
3. Interaction of nanoparticles with aquatic organisms
Among aquatic species, fish have been considered as the ideal sentinels to detect toxicological effects, due to their wide distribution, known physiology, and sensitivity to exposure to contaminants via food or water. In this chapter, some of the available studies with fish at different life stages (embryos, juveniles, and adults) are presented in Table 1.
|Primary particles||Study aim||Test organisms||Exposure protocol||Assessed endpoints||Main effects||References|
|Size: <100 nm||To assess developmental toxicity, oxidative stress, and DNA damage|
|Waterborne exposure to 1, 5, 10, 20, 50, and|
100 mg L−1 up to
144 h postfertilization
|Embryo/larvae survival, hatching, and malformation rates; ROS measurement; DNA damage; antioxidant enzymes; lipid peroxidation mRNA levels of genes encoding antioxidant proteins and regulation of ROS production||Reduction of hatching rate and induction of malformations; ROS generation; DNA damage|||
|Size: 25 nm||To identify potential mechanisms of cardiorespiratory effects of ZnO-NPs and characterize the ecophysiological importance of ZnO-NPs toxicity||Waterborne exposure for 25 h to 10 mg L−1; for 15 and 30 h to 1 mg L−1||Gill morphology, cardiorespiratory function||Damage to the gill epithelium; decreased heart acetylcholinesterase activity; reduction of aerobic capacity|||
|Size: 25 nm||To assess the effects of ZnO-|
NPs exposure in
the liver of a freshwater fish
|Waterborne exposure for 29.5 h to 1 mg L−1||Biomarkers of oxidative stress and antioxidant response||Changes in levels of hepatic enzyme activities, antioxidants, and lipid peroxidation products|||
|Size: 20 nm||To study stress proteomic responses|
|Waterborne exposure to 4 and 40 mg L−1 for 96 h||Molecular biomarkers (SOD, MT and HSP70)||Upregulation of HSP70|||
|Size: 30 nm||To evaluate bioaccumulation and subacute toxicity compared with bulk particles||Waterborne exposure (5–1000 mg L−) for 30|
|Accumulation in different tissues (gill, liver, intestine, muscle, and brain); histopathological changes; enzyme activities (e.g., Na+/K+ATPase, and SOD) nonenzymatic antioxidants and oxidative damage||Higher bioaccumulation, oxidative effect, and histopathological changes than bulk ZnO|||
|Size: 30 nm||To study Zn accumulation and the mechanism of hepatic detoxification in comparison with bulk ZnO and Zn2+||Waterborne exposure for 30 days to 2 mg L−1||Zn concentration and its subcellular distribution gills, liver, gut, and muscle||Tissue-specific bioaccumulation dependent on the exposed material|||
|Size: 15–350 nm||To compare the effects of zinc compounds in the form of nano-, microparticles and ions||Waterborne exposure to 0.2,|
2, 10 and 20 mg L−1 for 120 h
|Embryo/larvae survival, hatching, and malformation rates||Retardation of hatching and deviations in embryonic development; adherence of the particles on the egg surface at high ZnO-NPs concentrations|||
|Size: 50–60 nm||To compare the effect of different forms zinc (ZnO, ZnSO4, ZnO-NPs) on growth and hematological indices||Diet exposure|
(4% body weight
for 90 days
|Lethality, growth performance, food conversion ratio and efficiency, hepatosomatic index; blood parameters||Improvement in growth performance and red blood cell count with supplementation with ZnO-NPs compared to oxide and sulfate form|||
|Size: <100 nm||To evaluate the acute toxicity and hematological effects||Waterborne exposure to 30,|
50 and 70 mg L−1
for 96 h
|Blood parameters||96 h LC50 of ZnO-NPs between 100 and 110 mg L−1; chromosomal damages, changes in blood parameters|||
|Size: <100 nm||To evaluate the long-term effects|
of 3 sublethal concentrations
|Exposure for 21 days of three sublethal concentrations from the 96 h LC50 value (4.897 mg L−1)||Histopathological changes in the liver||Dose-dependent histological alterations generally associated with the response of hepatocytes to toxicants|||
|Size: <100 nm||To study the acute toxicity (LC50) and gill histopathology||Waterborne exposure for 96 h to 2, 4, 8, and 16 mg L−1; waterborne exposure to sublethal concentrations for 21 days||Lethality; gill histopathology||A 96 h LC50 of 4.897 mg L−1. Histopathological alterations in the gills at sublethal concentrations at higher concentrations|||
|Size: 30 nm||To quantify the trophic transfer of ZnO-NPs by feeding ||Fish exposure through diet for 14 days to ||Zn content on fish body burden||Uptake of both ZnO-NPs and ZnO-octyl NP with values exceeding by tenfold the levels obtained through aqueous exposure in other studies|||
|Size: 50 nm||To determine lethal concentration and histopathological lesions||Waterborne exposure for 24 h to 10–50 mg L−1||Lethal concentrations and histopathological alterations in gills, liver, kidney, and pancreas||Histopathological lesions in the kidney and gills; necrosis in liver, and hemorrhage in pancreas|||
As shown in Table 1, examples of recent research on ZnO-NPs interaction with fish have essentially focused on freshwater organisms such as
The effects of ZnO-NPs have been associated with two main mechanisms: oxidative stress and nanoparticle-protein interactions . Although some of the effects have been associated with the release of Zn ions as a result of particle dissolution, not all studies confirm that the toxic effects are due to dissolution. Higher bioaccumulation and effects have been observed after exposure to nanoparticle form when compared to bulk form, confirming the complexity and specificity of mechanisms associated with experimental conditions. Nonetheless, it is clear that more studies are needed, with lower concentrations and longer exposure periods, representing a more environmentally relevant scenario. There is also a clear need for studies on combined effects of abiotic factors variation (e.g., temperature, salinity, UV radiation), classical environmental contaminants (e.g., organic compounds, pesticide and pharmaceuticals), and ZnO-NPs, to represent an environmentally relevant scenario. There is also a need to assess the effects of ZnO-NPs in organisms present in high ionic strength environment (e.g., estuaries and marine environments). The information obtained in trophic transfer studies supports the concerns of potential effects of nanoparticles, to higher trophic levels in which humans may also be a target.
Considering the tested endpoints, the available data revealed that histological and hematological responses occur. After ZnO-NPs exposure, both juvenile and/or adult fish have shown its accumulation on tissues such as brain, liver, muscle, and gills [55, 56]. Hao et al.  reported ZnO-NPs accumulation on tissues of juvenile carp (
Several parameters such as hematological approaches have been used for the monitoring of health conditions of fish [58, 59]. Blood parameters as red and white blood cells count, hemoglobin content, and hematocrit value, and red blood cell indices are usually assessed on some toxicological studies. Although enhancement on red blood cell count was reported on the grass carp
Additionally, histology is also an important tool for the evaluation of fish health, showing the initial signs of lesions not easily noticeable during the macroscopic observation of tissues and organs . Gills are vital organs for respiration and osmoregulation. Gill histopathological alterations can be considered as indicators of the ZnO-NPs–induced toxicity in the common carp . Among other relevant organs, hepatic histopathological changes were documented as a result of exposure to ZnO-NPs [55, 61, 63].
As reported in Table 1, the ecotoxicological impacts of ZnO-NPs on fish include in most studies histopathological, hematological, and oxidative stress under different doses, protocols, and exposure [53, 55]. Tomilina et al.  reported decreased motility and increased curvature of tail in
In contrast, scarce data have demonstrated positive biological effects of ZnO-NPs. Reports on fish (
4. Potential impacts on public health
The hazard potential of ZnO-NPs to humans in comparison with microparticulate and dissolved Zn has been evaluated in the context of major accident prevention . Based on the analysis of endpoints of subtoxic events (inflammation, oxidative stress response, or gene expression profiling) over different timescales, the authors concluded that the hazard potentials of nano- and microparticles of ZnO are identical during acute (medium) and chronic (low) toxicity. Inhalation of ZnO fume and dust over the permissible exposure limit of 5 mg m−3 appears to be the riskiest toxic exposure, since Zn fume fever could be lethal . ZnO is quite soluble in acids and alkalies, thereby the toxicity of ZnO-NPs was also compared to that of zinc(II) ions. When considering the concentration of dissolved Zn, no significant differences between exposure to ZnO and ZnO-NPs have been found in EC50 and LC50 values, using
Zn is an essential trace element and micronutrient for humans. Under physiological conditions, it exists as a redox neutral divalent cation that is reactive as a Lewis acid. The continuous external supply of this metal ion is vital for many metabolic pathways, given that there is no body storage depot for zinc and its exchange between tissues is limited. The man body Zn content is approximately 2 g, and the recommended daily intake is 8–11 mg (tolerable upper intake level, 40 mg day−1). Bones and skeletal muscles contain more than half of the total body Zn, while the highest concentrations (>1 mg g−1 dry weight) are achieved in prostate gland . Around 0.1% of the total body zinc is replenished daily through diet, and it is equivalent to the percentage that is hold in blood serum (90 μg dL−1) .
Zinc homeostasis is tightly controlled at the whole body down to the subcellular level. In cells, half of the Zn content is in the cytoplasm, while nucleus and plasma membrane accounts for, respectively, 35 and 10% of the total cellular Zn . Since this metal ion is mainly bound to proteins (i.e., metallothioneins) and sequestered in organelles (i.e., mitochondria, endoplasmic reticulum, Golgi apparatus, secretory granules, and other vesicular compartments), the cytosolic free Zn concentration is in the picomolar/nanomolar range. In the cytosol, Zn concentrations fluctuate in wave and spark manners, of which regulatory mechanism still not completely understood. Zinc transporters (ZnTs) are of outstanding importance for the cellular and subcellular zinc homeostasis (Table 2), since ions cannot be synthesized or broken down by cells. ZnT transporters (ZnT1-ZnT10) belong to the Solute Carrier Family 30A (SLC30A). This protein “Family” also comprises another group of proteins that translocate Zn across membranous barriers, the ZIP transporters (ZIP1-ZIP14). However, ZIP transporters are involved not only in Zn transport but also in the homeostasis of cadmium, manganese, iron, and calcium .
|Name||Main functions at subcellular level||Entries: Protein/Gen*|
|Zn2+ efflux through plasma membrane. Negative regulation of Zn2+ and Ca2+ transmembrane import and neurotransmitter secretion||Q9Y6M5 (ZNT1_HUMAN)/SLC30A1|
|Zn2+ transmembrane transport (accumulation in endosomes, lysosomes, and secretory vesicles in mammary epithelial cells). Regulation of sequestering of and response to Zn2+||Q9BRI3 (ZNT2_HUMAN)/SLC30A2|
|Zn2+ transporting ATPase (accumulation in synaptic vesicles, late endosomes, and lysosomes). Regulation of sequestering of and response to Zn2+||Q99726 (ZNT3_HUMAN)/SLC30A3|
|Zn2+ transmembrane transport (transport out of the cytosol—accumulation in endosomes, lysosomes, secretory vesicles, and trans-Golgi network)||O14863 (ZNT4_HUMAN)/SLC30A4|
|Zn2+ transmembrane transport into lumens of|
the Golgi apparatus and early compartments of
the secretory pathway such as COPII-coated
vesicles (putative transporter of Zn2+ into β cells in
order to form insulin crystals). Required with
ZnT7 for the activation of Zn-requiring enzymes,
alkaline phosphatases, and ZnT6 and ZnT7 for
the activation of TNAP
|Zn2+ efflux transporter that allocates it to trans-Golgi network and vesicular compartment. Regulation of sequestering of and response to Zn2+||Q6NXT4 (ZNT6_HUMAN)/SLC30A6|
|Zn2+ transmembrane transport into lumens of Golgi apparatus and vesicular compartments. Required for activation of alkaline phosphatases and with ZNT5 and ZNT6 for the activation of TNAP||Q8NEW0 (ZNT7_HUMAN)/SLC30A7|
|Zn2+ efflux transporter which allocates it to intracellular vesicles (i.e., accumulation into insulin granules in pancreatic β cells, providing Zn2+ to insulin maturation and/or storage). Regulation of sequestering of and response to Zn2+. Responsiveness to glucose, γ-interferon, and interleukin-1||Q8IWU4 (ZNT8_HUMAN)/SLC30A8|
|Role in the p160 coactivator signaling pathway that mediates transcriptional activation by nuclear receptors. Transcriptional activation of Wnt-responsive genes||Q6PML9 (ZNT9_HUMAN)/SLC30A9|
|Zn2+ transmembrane transport into Golgi apparatus and early endosomes. Regulation of sequestering of and response to Zn2+||Q6XR72 (ZNT10_HUMAN)/SLC30A10|
|A major Zn2+ uptake transporter in many cells; responsible for the rapid uptake and accumulation of physiologically effective Zn in prostate cells||Q9NY26 (S39A1_HUMAN)/SLC39A1|
|Zn2+ transport through the plasma membrane (uptake mediated by Zn2+-HCO3− symport). It is involved in contact inhibition of normal epithelial cells, and loss of its expression is related to tumorigenesis||Q9NP94 (S39A2_HUMAN)/SLC39A2|
|Zn2+ transport through the plasma membrane (influx to cytosol). It is involved in cell morphogenesis and T cell homeostasis||Q9BRY0 (S39A3_HUMAN)/SLC39A3|
|Zn2+ transmembrane transport (influx to cytosol)|
It is involved in the regulation of cellular Zn homeostasis in response to Zn2+ availability (cycles between endosomal compartments and the plasma membrane)
|Zn2+ transmembrane transport (serosal to mucosal) through basolateral cell membrane in polarized cells||Q6ZMH5 (S39A5_HUMAN)/SLC39A5|
|Zn2+ transport through the plasma membrane (influx to cytosol)||Q13433 (S39A6_HUMAN)/SLC39A6|
|Zn2+ transmembrane transport from the endoplasmic reticulum/Golgi apparatus to the cytosol that is stimulated by growth factors (EGF), Ca2+and exogenous Zn2+||Q92504 (S39A7_HUMAN)/SLC39A7|
|Zn2+ transport through the plasma membrane and endosomal and lysosomal membranes (influx and release to cytosol)||Q9C0K1 (S39A8_HUMAN)/SLC39A8|
|Zn2+ transport through the plasma membrane and trans-Golgi network membrane (influx and release to cytosol)||Q9NUM3 (S39A9_HUMAN)/SLC39A9|
|Zn2+ transport through the plasma membrane (influx to cytosol). Positive regulation of B cell proliferation, B cell receptor signaling pathway, and protein tyrosine phosphatase. Negative regulation of B cell apoptotic process||Q9ULF5 (S39AA_HUMAN)/SLC39A10|
|Zn2+ transport through the trans-Golgi network membrane (release to cytosol)||Q9NUM3 (S39A9_HUMAN)/SLC39A9|
|Zn2+ transport at the plasma membrane, nucleus, and Golgi apparatus (influx and release to cytosol). Regulation of microtubule polymerization, neuron projection development, and signal transduction||Q504Y0 (S39AC_HUMAN)/SLC39A12|
|Zn2+ transmembrane transport in the Golgi apparatus (release to cytosol)||Q96H72 (S39AD_HUMAN)/SLC39A13|
|Zn2+ transport through the plasma membrane (influx to cytosol). Broad-scope metal ion transporter with a preference for Zn2+ uptake (cellular uptake of nontransferrin-bound Fe)||Q15043 (S39AE_HUMAN)/SLC39A14|
|Zinc finger protein 593 negatively modulates the transcriptional regulatory activity of Oct-2||O00488|
|Teashirt homolog 2 is a putative transcriptional regulator in developmental processes, acting as transcriptional repressor||Q9NRE2|
|Transcription factor Sp9 positively regulates FGF8 expression in the apical ectodermal ridge and contributes to limb outgrowth in embryos||P0CG40|
|Transcriptional repressor scratch 1 binds E-box motif CAGGTG and modulates the basic helix-loop-helix transcription factors during neuronal differentiation||Q9BWW7|
|Sal-like protein 4 is an important transcription factor in the maintenance and self-renewal of embryonic and hematopoietic stem cells||Q9UJQ4|
|Protein odd-skipped-related 1 is a transcription factor in the regulation of embryonic heart and urogenital development||Q8TAX0|
|Zinc finger Y-chromosomal protein is a transcriptional activator through binding to the consensus sequence 5’-AGGCCY-3’||P08048|
|Zinc finger protein 57 homolog is a transcription regulator that binds to a 5’-TGCCGC-3’ consensus sequence and recognizes the methylated CpG within this element. It is important for the maintenance of maternal and paternal gene imprinting through control of DNA methylation during the earliest multicellular stages of development at multiple imprinting control regions||Q9NU63|
|Zinc finger and BTB domain-containing protein 18 is a transcriptional repressor that binds to the consensus DNA sequence 5’-[AC]ACATCTG[GT][AC]-3’ containing E-box core. It is involved in the recruitment of chromatin remodeling multiprotein complexes, the regulation of skeletal myogenesis, progenitor cell division, and postmitotic cortical neurons survival||Q99592|
|Hypermethylated in cancer 1 protein is a transcriptional repressor that recognizes and binds to the consensus sequence ‘5-[CG]NG[CG]GGGCA[CA]CC-3’. It regulates the Wnt signaling pathway, p53/TP53-dependent apoptotic DNA damage responses, and the transcription of CCND1/cyclin-D1 and CDKN1C/p57Kip2 in quiescent cells. May act as a tumor suppressor and is involved in development of head, face, limbs, and ventral body wall||Q14526|
|Krueppel-like factor 1 is a transcription regulator of erythrocyte development and switch factor during erythropoiesis. When sumoylated, acts as a transcriptional repressor by promoting interaction with CDH2/MI2β and represses megakaryocytic differentiation||Q13351|
|Ikaros C2H2||DNA-binding protein Ikaros has transcription regulator activity, via binding to γ-satellite DNA, which is isoform-specific and modulated by dominant-negative inactive isoforms. It increases normal apoptosis in adult erythroid cells and confers early temporal competence to retinal progenitor cells||Q13422|
|Both isoforms of zinc finger protein GLI1 are transcriptional activators that bind to the DNA consensus sequence 5’-GACCACCCA-3’, but activate different sets of genes. Isoform 1 plays a role in cell proliferation and differentiation, through SHH signaling pathway, whereas isoform 2 activates CD24 expression. Promotes cancer cell migration||P08151|
|E3 SUMO-protein ligase EGR2 is a transcription factor that binds to two sequence-specific DNA sites located in the promoter region of HOXA4. Supports SUMO1 conjugation to coregulators NAB1 and NAB2, whose sumoylation downregulates EGR2 own transcriptional activity||P11161|
|Zinc finger protein DZIP1 interaction with DAZ supports the participation in spermatogenesis and primary cilia formation through Hedgehog signaling pathway||Q86YF9|
|Zinc finger E-box-binding homeobox 1 is a transcriptional repressor that positively regulates neuronal differentiation and promotes tumorigenicity||P37275|
|Transcriptional repressor CTCF plays important roles in gene silencing, chromatin remodeling, interchromosomal association, regulation of epigenetic modifications, oocyte and preimplantation embryo development. It is also a putative tumor suppressor||P49711|
|Zinc finger protein AEBP2 is a DNA-binding transcriptional repressor that stimulates PRC2 complex activity||Q6ZN18|
|D-Lactate dehydrogenase (acceptor)||220.127.116.11||Alanine metabolism|
|Formaldehyde dismutase||18.104.22.168||Contains a tightly but noncovalently bound NADP(H) cofactor, as well as Zn2+ and Mg2+|
|Peptide-methionine (R)-S-oxide reductase||22.214.171.124||Selenoprotein. Prevention of oxidative stress damage caused by reactive oxygen species by reducing the oxidized form of methionine back to methionine and thereby reactivating peptides that had been damaged|
|Superoxide dismutase||126.96.36.199||Degradation of reactive oxygen species and superoxide radicals|
|Histone acetyltransferase||188.8.131.52||Different specificities toward histone acceptors|
|RING-type E3 ubiquitin transferase||184.108.40.206||Degradation of misfolded protein|
|Protein geranylgeranyltransferase type I||220.127.116.11||Zn metalloenzyme. Zn2+ is required for peptide, but not for isoprenoid, substrate binding. Inhibition induces simultaneous p53-dependent apoptosis and autophagy in airway smooth muscle cells|
|Tyrosine transaminase||18.104.22.168||Involved in multiple metabolic pathways|
|Riboflavin kinase||22.214.171.124||Mg2+ is preferentially required for activity. Essential in recruiting Nox1 to death receptor4/5, critical role in the KD548-Fc-mediated reactive oxygen species accumulation and coupling of TNF-receptor-1 to NADPH oxidase|
|Rhodopsin kinase||126.96.36.199||Inhibited by Zn2+|
|β-Adrenergic-receptor kinase||188.8.131.52||Inhibited by Zn2+|
|tRNase Z||184.108.40.206||Involved in both, nuclear and mitochondrial tRNA 39 end maturation and in the p53 signaling pathway|
|N-acetylphosphatidylethanolamine-hydrolyzing phospholipase D||220.127.116.11||Contains Zn2+ and is activated by Mg2+ or Ca2+. It does not hydrolyze phosphatidylcholine and phosphatidylethanolamine|
|Aminopeptidase B||18.104.22.168||Exopeptidase strictly specific for the removal of N-terminal basic residues from peptides and proteins|
|Xaa-Trp aminopeptidase||22.214.171.124||Zn2+containing glycoprotein from renal and intestinal brush border membranes|
|Aminopeptidase I||126.96.36.199||Activity is stimulated by both Zn2+ and Cl−|
|N-acyl-aliphatic-L-amino acid amidohydrolase||188.8.131.52||Contains Zn2+ (completely inactivated by metal removal, whereas addition of Zn2+, Mn2+, or Fe2+ restores activity). It is involved in the hydrolysis of |
|Cu2+-exporting ATPase||184.108.40.206||Zn binds with a stoichiometry of 6–1 and induces a conformational change in the N-terminal domain that is different from those observed for Co binding, leading to a loss of secondary structure in the domain|
|Mitochondrial protein-transporting ATPase||220.127.116.11||A nonphosphorylated, non-ABC (ATP-binding cassette) ATPase involved in the transport of proteins or preproteins into mitochondria using the TIM protein complex|
|Porphobilinogen synthase||18.104.22.168||Contains Zn2+ at the active site. Essential for respiration and a primary target in Pb intoxication|
|Ubiquitin-protein ligase||22.214.171.124||Crucial role in the recognition and degradation of target proteins by 26S proteasomes|
Zn ions are important for the regulation of central biochemical processes (gene transcription and the metabolism of lipids, proteins, and nucleic acids), which impacts a variety of physiological functions (e.g., neuronal, endocrine, skeletal, reproductive, immune, and healing). It is estimated that the 10% of the proteins (around 3000 proteins) encoded in the human genome are zinc proteins . According to the last release of the UniProtKB/Swiss-Prot database, more than one hundred of human proteins are zinc finger (ZnF) macromolecules (Table 2). Apart from the structural role of Zn in ZNFs , which contributes to shape the zinc-binding repeats as molecular scaffolds for tight binding of their target molecules (DNA, RNA, other proteins, or lipids), this metal ion is also essential for enzyme catalysis and cell signaling (Table 2) [73, 74]. In enzyme catalytic centers, Zn often promotes substrate activation by stabilizing negative charges due to strong Lewis acid properties. The metal ion acts as endocrine, paracrine, autocrine, and intracrine mediator. In cells, the distribution of Zn is modified by the stimulation that triggers its release in the central nervous and neuroendocrine systems. Zn is also a ubiquitous cytosolic second messenger, leading to fast alteration of signaling enzyme activities (i.e., phosphodiesterases, mitogen-activated protein kinase, protein kinase C, protein tyrosine phosphatases, calcineurin, caspases) and afterward to the biosynthesis of proteins that control its cytosolic concentrations. Interestingly, Zn accumulation in specific subcellular compartments appears to occur during both physiological and pathological conditions. For instance, the Zn spark that follows the calcium wave during fertilization is thought to be crucial for further cell cycle resumption in eggs . Accumulation of Zn in lysosomes is a common observation during neurodegenerative processes and intoxication .
In humans, symptoms of Zn deficiency include: severe anemia, persistent diarrhea, immune insufficiency ensuing recurrent inflammations and impairment of wound healing, growth retardation, hypogonadism, skin and eyes abnormalities, baldness mental lethargy, brain dysfunctions, and behavioral changes. Zn deficiency still continues a global public health concern, particularly in developing countries where it causes mortality among young children . Conversely, minor Zn deficiency among elderly population and individuals who undergo gastric bypass surgery for obesity seems to be increasing in industrialized countries. Thereby, development of high efficient Zn-enriched nutritional supplements could be advantageous in decreasing the incidence of degenerative and immunodeficiency disorders, infections, and persistent diarrhea. Current Zn formulations better absorbed through supplements are in the form of picolinate or chelates of amino acids. Duodenum is the principal site for Zn absorption. Therefore, intestinal pathologies that cause poor micromineral absorption, such as Crohn’s disease, can also induce Zn malabsorption. Other metal ions, such as Ca2+, Fe2+, and mostly Cu2+ compete with Zn2+ during translocation from the apical surface of the villae to the basolateral surface of enterocytes. In matter of fact, Zn intake close to the recommended dietary allowance (15 mg/day) may cause copper and iron deficiency and adversely affect HDL cholesterol concentrations. Overt symptoms of Zn poisoning (i.e., nausea, vomiting, epigastric pain, lethargy, and fatigue) usually occur only after exposure to extremely high Zn levels .
Zn-related diseases might be prompted either when its scarcity and overload go beyond the limited cellular Zn buffering capacity, which seems to be rather sensitive to environmental factors. Apparently, healthy individuals tolerate up to 10-fold changes of the recommended daily intake of Zn . Whether exposure to Zn concentrations outside the physiological range promotes salutary or injurious effects depends on Zn concentration. Different ranges of Zn concentration appear to be required for exhibiting beneficial properties as antioxidant, antiinflammatory, and antiapoptotic agent . Intriguingly, both Zn excess and scarcity undermine the loosely equilibrium toward prooxidant, proinflammatory and proapoptotic actions.
Lung toxicity after inhalation of ZnO-NPs is likely the most documented deleterious effect in the literature. The severity of ZnO-NPs-induced inflammatory condition is significantly correlated with the mass and surface area of the nanoparticles, suggesting that the toxic effect of ZnO-NPs is mainly caused by the release of Zn ions . It is also claimed that intact ZnO-NPs have a unique way of inducing inflammatory effects compared with dissolved Zn ions . For example, ZnO-NPs may either stimulate the production of IFN-γ and subsequent macrophage activation, neutrophilic infiltration, and fibrosis (Th1 inflammatory response) or cause a mixed inflammatory cell immune response by triggering a Th2 response . Inhaled ZnO-NPs, through the olfactory bulb–brain translocation pathway, could also induce neurotoxic effects by activation of astrocytes and microglia, which causes neuroinflammation [84, 85].
Recently, a battery of tests, including hemolytic and oxidative stress markers,
The pharmaceutical industry makes use of Zn(II) compounds (ZnCl2, ZnO, zinc pyrithione, Zn(CH3CO2)2) as active substances, lubricants, and emollients for a long time . Usually, zinc-containing medicines are intended to topic application as wound healings, anti-infectious, disinfectants, and lubricants (Table 3). Apart from ZnO-NPs use in pharmaceutical formulations (i.e., drug delivery) and medicine (i.e., bioimaging), they are also present in a large number of consumer products (protective sunscreens, hair care formulations, cosmetics, supplements, food additives, etc.), as already mentioned above (Section 1). Recently, the European Council on Cosmetic Products (The European Commission (2016), Commission Regulation (EU) 2016/621 of 21 April 2016) restricted the use of ZnO-NPs in spray products because it could lead to exposure of the consumer’s lungs to ZnO-NPs by inhalation, and encouraged only oral and dermal use of ZnO-NPs, up to a maximum concentration in ready for use preparation of 25%, with the following characteristics: (i) purity ≥96%, with
Up to date information highlights not only the genotoxicity and cytotoxicity of ZnO-NPs due dissolution, ROS generation, immunomodulatory, and apoptotic responses, but also their selective cytotoxicity [82, 89–93]. In general, cytotoxicity is thought to be a collateral effect to avoid. To evaluate the specific risks and benefits of human exposure to ZnO-NPs, its size, shape, degradability, agglomeration/aggregation propensity, adsorption ability, specific surface area, and interfacial chemical and physical reactivity should be considered intrinsic properties, which likely influence their biopersistence, cellular interactions, and bioactivities when compared with microparticulate and dissolved Zn during intentional and unintentional human exposures. For instance, ZnO-NPs sized 20–25 nm appear to exhibit higher antibacterial and antifungal activity than other ZnO forms . Sublethal concentrations of ZnO-NPs (surface area of 10.7 ± 0.7 nm) reduce the mitochondrial membrane potential, leading to a dose-dependent increase in gluconeogenesis and glycogenolysis, which could not be only attributed to dissolution of ZnO-NPs in extracellular fluids . Kao et al.  proposed that ZnO-NPs are mainly internalized by endocytosis and dissolved in endosomes, raising the cytosolic free Zn2+ concentration, which is further sequestrated by mitochondria leading to cell apoptosis, due to mitochondrial dysfunction and caspases activation. ZnO-NPs readily dissolve in artificial lysosomal fluid (pH 4.5), but form aggregates and precipitates in the slight alkaline interstitial fluid .
|Zinc compound||Route of administration||Role in formulation||Target organ||Clinical recommendations|
|Zinc acetate||Topic||Active ingredient: antibacterial action||Skin||Treatment of inflammatory acne, characterized by bacterial involvement|
|Zinc chloride||Topic||Active ingredient: antibacterial, analgesic, and healing actions||Mouth/oropharynx||Treatment of gingivitis and stomatitis; relief of toothache; oral hygiene|
|Zinc oxide||Topic||Active ingredient: adjuvant of healing||Skin||Treatment of diaper dermatitis|
|Topic||Emollient/lubricant: antihemorrhoidal action||Anus/lower rectum||Symptomatic treatment of hemorrhoids|
|Topic||Emollient/lubricant: soothing, smoothing, and moisturizing actions||Skin||Symptomatic treatment of dry and scaly lesions, especially of ichthyosis, psoriasis, and eczema Disinfection and hygiene of the skin and mucous membranes, superficial wounds, and diaper dermatitis|
|Zinc pyrithione||Topic||Active ingredient: antibacterial and antifungal actions||Skin||Treatment of pityriasis versicolor, tinea pedis, psoriasis, seborrheic dermatitis, eczema, and vitiligo|
In contract with small molecules that are translocated across the plasma membrane by passive diffusion or active transport, nanosized particles are internalized by cells mainly through endocytosis. This feature of NPs offers a myriad of opportunities for specific cellular targeting, controlled drug delivery, and bioimaging. The endocytotic capability varies significantly among cellular populations. Phagocytes (i.e., macrophages, monocytes, neutrophils, dendritic, and mast cells) are chemotaxing cells that move toward site of infections causing inflammation, play a central role in innate immunity response, and stimulate lymphocytes to produce antibodies (adaptive immunity) by antigen presentation. ZnO-NPs coating that favors interaction with opsonin, scavenger, or Toll-like receptors should enhance selective internalization by phagocytes. Uncoated ZnO-NPs should also be engulfed by lymphocytes, erythrocytes, fibroblasts, epithelial, and endothelial cells. Given that ZnO-NPs are microscopic particle with at least one dimension less than 100 nm, they can be internalized by any living cell by micro- and pinocytosis. The subcellular availability of ZnO-NPs should greatly depend on the specific endocytotic pathway (i.e., clathrin-dependent, caveolae-dependent, clathrin- and caveolae-independent, receptor-mediated) involved in the internalization process. For instance, ZnO-NPs loaded in caveolae vesicles may reach the endoplasmic reticulum and the nucleus, since caveosomes are pH neutral multivesicular bodies . Conversely, internalization of ZnO-NPs through LDL receptor-mediated endocytosis should raise the cytosolic zinc ion significantly, due to dissolution of ZnO in the acidic lysosomal environment. Accordingly, it has been experimentally demonstrated by using ICP-MS and fluorescent-labeled ZnO dissolution occurs in endosomes, and that nondissolved ZnO-NPs enter caveolae in BEAS-2B cells (human bronchial epithelial cells) and enter lysosomes in RAW 264.7 cells (mouse leukemic monocyte macrophage cell) in which smaller particle remnants dissolve . In the support of cell-specific behavior of stable aqueous solutions of monodispersed ZnO-NPs is the fact that ZnO-NPs doses exhibiting negligible cytotoxic effects to osteogenically differentiated mesenchymal stem cells were lethal to proliferating pluripotent mesenchymal stem cells . As already mentioned above (Section 1), ZnO-NPs selectively induce apoptosis, mediated by reactive oxygen species via p53 pathway, in cancer cells (human hepatocellular carcinoma HepG2, human lung adenocarcinoma A549, and human bronchial epithelial BEAS-2B), but did not affect normal astrocytes and hepatocytes . Thereby, to better explore therapeutic advantages and prevent unwanted cytotoxic effects and the potential of ZnNPs in terms of clinical diagnosis, it is important to perform a holistic analysis of the characteristics of ZnNPs, the administration route, the zinc body burden, the target cells, and the relevant physiological processes in each specific case.
5. Conclusions, next steps, and opportunities
The ever increasing literature on ZnO-NPs clearly demonstrates the current value and applications of these particles and tremendous potential for future applications. There are a large number of challenges associated with its safe use, when compared with commonly tested substances. As for other nanoparticles, the advantages have to be carefully weight against potential pernicious effects. The currently available data clearly demonstrate the ability of ZnO-NPs to induce acute effects on fish, although at concentrations higher than those estimated to be present in the environment. Nonetheless, the long-term effects are yet to be explored. The considerable lack of information in terms of how these particles are released in the environment, at which levels, and in what form make the establishment of maximum allowed concentration a difficult task, based on available toxicity tests. More studies have to be conducted to explore the behavior of particles upon alterations of receiving media characteristics (e.g., ionic strength UV/radiation) and their fate. This information is essential for environmentally relevant ecotoxicological studies.
It is expected that, in the very near future, advances in analytical techniques allow quantification and accurate characterization of nanoparticles in environmental matrices which will allow the establishment of potentially impacted areas, monitoring of levels and effects on biota from those sites. Also, the need to the development of more effective wastewater treatments will potentially reduce the risk of the increased production of nanoparticle containing materials.
As can be seen from the literature, a broad range of applications of nanomaterials, in particular ZnO-NPs, exists on human activities. In this chapter, the benefits of ZnO nanomaterials are clearly recognized on a myriad of applications, having a great potential for the diagnosis, imaging, drug delivery, and treatment of several pathologies. Other areas within agricultural domain and energy resources have also relevant applications. Moreover, great potentials for their applications on aquaculture improving fish growth were documented.
The disposal and fate of ZnO-NPs into the environment may represent a risk to aquatic biota. This chapter highlights the significance in considering their fate and behavior into water bodies and its role on aquatic organisms, particularly fish. The published literature undoubtedly illustrates that ZnO-NPs have different toxic effects on microorganisms, rodents, human cells, and fish depending on their physicochemical features. In addition, the trophic transfer of these nanomaterials to humans through diet (i.e., by consuming contaminated fish) warrants special care. Therefore, disposal of ZnO-NPs deserves more attention since bioaccumulation of these elements may occur on aquatic species with impact on both human and environmental health. Precaution and more strict rules must be delimited for disposal of ZnO-NPs into the aquatic environments.
Zinc ion homeostasis is vital for humans and is closely linked with the homeostasis of other metal ions, particularly iron and copper. Nowadays, hypozincemia and hyperzincemia are two pathophysiological conditions of which enduring prevalence is also related to malnutrition during aging and emerging lifestyle diseases (i.e., obesity) in industrialized countries. While the risks of using ZnO-NPs are not fully understood, the advantages of its emerging applications, including in the therapeutic and diagnostic areas, are already widely recognized. Probably, the toxicity of ZnO-NPs for man is not superior to the zinc ion itself, and nanoparticulate forms appear to enable interaction with specific cell cycle states (i.e., proliferating cells) and selective interference with important physiological processes, allowing not only selection of the administration route of ZnO-NPs but also the cellular internalization pathway and further intracellular distribution.
The balance of the positive aspects of these nanomaterials and risks caused in some aquatic species, particularly on fish, targeting possible implications for human health deserve a continuous monitoring. Although safety measures have been assumed during industrial production, storage, and removal of these nanomaterials, a constant monitoring of possible risks for aquatic life and ultimately humans is needed.
As a general conclusion, it is expected that in the near future, there is an increase in the use of ZnO-NPs for various purposes. Comprehensive understanding of their toxic effect is needed for their prolonged use.
This chapter was funded by project CICECO – Aveiro Institute of Materials, POCI-01-0145-FEDER-007679 (Foundation for Science and Technology—FCT Ref. UID/CTM/50011/2013), financed by national funds through the FCT/MEC and when appropriate cofinanced by FEDER under the PT2020 Partnership Agreement; also CICECO scholarships were given to A. Begam and P. Prasad, respectively, (BIC/UI89/7424/2016; BIC/UI89/7426/2016) added to the support of Mahatma Gandhi University, Kerala, India.